SCHEMBL6648239

SCHEMBL6648239

c1ccc(CCCn2cncn2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 2/20 0.62
SMN1; SMN2 Q16637 4/20 0.60
LMNA P02545 3/20 0.60
NPC1 O15118 3/20 0.60
RAB9A P51151 3/20 0.60
TP53 P04637 3/20 0.60
MAPT P10636 2/20 0.60
NFKB1 P19838 1/20 0.60
NFKB2 Q00653 1/20 0.60
RELA Q04206 1/20 0.60
KDM4E B2RXH2 2/20 0.55
MEN1 O00255 1/20 0.55
KMT2A Q03164 1/20 0.55
TSHR P16473 1/20 0.51
MAPK1 P28482 1/20 0.50
ALDH1A1 P00352 2/20 0.48
TDP1 Q9NUW8 1/20 0.48
SIGMAR1 Q99720 1/20 0.47
POLB P06746 1/20 0.47
EGLN3 Q9H6Z9 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7138301 0.89 CYP19A1 (0.67) CYP19A1SMN1; SMN2LMNANPC1RAB9A
SCHEMBL5654351 0.83 ALDH1A1 (0.47) CYP19A1SMN1; SMN2LMNANPC1RAB9A
SCHEMBL5759428 0.82 SMN1; SMN2 (0.79) SMN1; SMN2LMNANPC1RAB9ATP53
SCHEMBL31415781 0.82 CYP19A1 (0.54) CYP19A1SMN1; SMN2LMNANPC1RAB9A
SCHEMBL24041752 0.81 LMNA (0.71) SMN1; SMN2LMNANPC1RAB9ATP53
SCHEMBL23609486 0.81 LMNA (0.49) CYP19A1SMN1; SMN2LMNANPC1RAB9A
SCHEMBL8545347 0.80 SIGMAR1 (0.53) SIGMAR1
SCHEMBL23861179 0.79 CYP19A1 (0.54) CYP19A1SMN1; SMN2LMNANPC1RAB9A
SCHEMBL30927861 0.78 MEN1 (0.62) CYP19A1SMN1; SMN2LMNANPC1RAB9A
SCHEMBL5759143 0.78 ALDH1A1 (0.52) CYP19A1SMN1; SMN2LMNANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040133008-A1 Amide compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-07-08 US disclosed
WO-2004039795-A2 AMIDE COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-05-13 WO disclosed
EP-0023637-B1 SUBSTITUTED 2,3-DIHYDROBENZOFURYLMETHYL-CYCLOPROPANECARBOXYLIC ACID ESTERS, PROCESS FOR THEIR PREPARATION, PROCESS FOR COMBATTING PARASITES, AND AGENTS THEREFOR BASF Aktiengesellschaft (DE) 1984-04-04 EP disclosed
US-4344961-A MITICIDES BASF AKTIENGESELLSCHAFT (DE) 1982-08-17 US disclosed
US-4315017-A Triazole derivatives BASF AKTIENGESELLSCHAFT (DE) 1982-02-09 US disclosed
US-4298615-A INSECTICIDES, MITICIDES BASF AKTIENGESELLSCHAFT (DE) 1981-11-03 US disclosed
EP-0008651-B1 DERIVATIVES OF TRIAZOLE, PROCESS FOR THEIR PRODUCTION AND INSECTICIDES CONTAINING THEM BASF Aktiengesellschaft (DE) 1981-10-14 EP disclosed
EP-0023637-A1 Substituted 2,3-dihydrobenzofurylmethyl-cyclopropanecarboxylic acid esters, process for their preparation, process for combatting parasites, and agents therefor BASF Aktiengesellschaft (DE) 1981-02-11 EP disclosed
EP-0012273-A1 Carboxylic acid esters, process for their preparation and their use as pesticides BASF Aktiengesellschaft (DE) 1980-06-25 EP disclosed
EP-0008651-A1 Derivatives of triazole, process for their production and insecticides containing them BASF Aktiengesellschaft (DE) 1980-03-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040133008-A1 Amide compounds APOB, APOL1, LDLR CYP19A1 860/4885SMN1; SMN2 1836/4885LMNA 1410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.